[PRESS RELEASE] – CHICAGO, Sept. 15, 2025 – Verano Holdings Corp., a leading multistate cannabis company, announced that the company’s board of directors approved, and the company will be seeking shareholder approval of, a proposed plan to redomicile Verano Holdings Corp. from British Columbia, Canada, to the state of Nevada.

Verano believes that redomiciling in the United States better aligns with its U.S.-based business and operations and streamlines its organizational and regulatory structure within the United States, among other reasons discussed in the preliminary proxy statement filed by the company on Sept. 12, 2025, with the U.S. Securities and Exchange Commission and in Canada on SEDAR+ (the “preliminary proxy statement”).

“Since inception and our 2021 go-public transaction, we’ve focused on ways to unlock shareholder value and create potential catalysts for the business, including enhancements to our corporate structure and executing a capital markets strategy that positions Verano to capitalize on near and long-term growth opportunities,” Verano Chairman and CEO George Archos said. “From our 2023 strategic decision to list company shares on Cboe Canada, a senior U.S.-based exchange with global operations, to our redomiciling in the U.S. as a newly-registered Nevada enterprise, we are prepared to leverage opportunities that benefit the company and our shareholders.”

The company’s plan to redomicile Verano Holdings Corp. in the United States is not expected to materially impact its existing manufacturing and retail business, which spans 13 U.S. states, including the location of its corporate headquarters in Chicago.

Pursuant to the company’s proposed plan of arrangement, Verano will continue from the jurisdiction of British Columbia, Canada, to the jurisdiction of the state of Nevada (the “continuance”). Upon completion of the continuance, the issued and outstanding subordinate voting shares of the British Columbia-formed Verano Holdings Corp. will automatically be exchanged on a one-for-one basis for shares of common stock of the continued Verano Holdings Corp. domiciled in Nevada (“Nevada common stock”). Each of the company’s outstanding stock options and restricted stock units will be deemed to be adjusted pursuant to the terms of the company’s stock and equity incentive plan to become a stock option and a restricted stock unit to receive an equal number of shares of Nevada common stock, respectively.

The preliminary proxy statement was filed in connection with a proposed special meeting of the company’s shareholders to consider and, if thought advisable, approve a plan of arrangement implementing the continuance. The company’s board of directors may, at any time, including after receiving shareholder approval, in its discretion, decide not to proceed with the arrangement and not complete the continuance.

Upon completion of the continuance, the Nevada common stock will trade on the Cboe Canada exchange under the company’s existing ticker symbol, “VRNO,” and be quoted on the OTCQX under the symbol “VRNOF.”

For more information on Verano Holdings Corp., visit the company’s investor website: https://investors.verano.com/.

New York lawmakers have scheduled a hearing to discuss the medical potential of psilocybin as the state considers pursuing a pathway for regulated access to the main psychedelic component of “magic mushrooms.”

In a notice published by the Assembly Health Committee on Wednesday, Chairwoman Amy Paulin (D) noted that, while psilocybin is currently listed as a Schedule I drug, the federal Food and Drug Administration (FDA) has designated it as a “breakthrough therapy” for major depression—indicating that “the therapy may offer improved results for such conditions over currently approved treatments.”

A meeting to go over the science and potential regulations of the novel therapy is scheduled for September 30. Oral testimony is by invite only from the committee, and witnesses have not yet been announced.

“Various localities have enacted measures regarding psilocybin, including the states of Colorado, Oregon, and New Mexico which allow for its supervised use, citing its potential as a treatment for some mental health conditions,” the notice says. “However, more information is needed to better understand the medicinal value that psilocybin may have as a therapy in New York State.”

“To this end, the Committee seeks to hear from researchers, medical experts, and other stakeholders on the potential medicinal value and risks of psilocybin,” Paulin said.

The chairwoman introduced a bill to legalize psilocybin for adults last year, provided they obtain a permit after undergoing a health screening and educational course.

New York legislators have taken special interest in psychedelics reform in recent sessions.

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

For example, in January, Assemblymember Linda Rosenthal (D) filed legislation calling for the legalization of certain entheogenic substances such as psilocybin and ibogaine for adults 21 and older.

The bill would amend state statute to make legal the “possession, use, cultivation, production, creation, analysis, gifting, exchange, or sharing by or between natural persons of twenty-one years of age or older of a natural plant or fungus-based hallucinogen.”

DMT, ibogaine, mescaline, psilocybin and psilocyn would fall under the definition of “natural plant or fungus-based hallucinogens” that would be legalized by the bill.

Rosenthal’s measure was introduced just days after another New York lawmaker, Sen. Nathalia Fernandez (D), prefiled a measure that would legalize psilocybin therapy for patients with qualifying conditions.

Under that proposal, people could receive psilocybin treatment from a certified facilitator in a clinical setting, or at their home if they’re unable to travel. Patients and facilitators would receive protections against state-level prosecution.

Fernandez also filed an earlier version of the bill last session, but it did not move out of committee either. Only minor technical changes have been made in the latest iteration.

Bicameral New York lawmakers said at a briefing last year that there was a “real chance” that legislation to legalize psilocybin-assisted therapy would advance through committee, emphasizing that delaying action would “neglect” many “people who need help” with certain mental health conditions. That did not ultimately materialize, however.

“We’re in a mental health crisis, and so we need every tool that’s available to us,” Assemblymember Pat Burke (D), who sponsored another bill to create a psilocybin therapy pilot program for 10,000 people, said. He added that “we’re here to turn the page” on the broader drug war.

Photo courtesy of Dick Culbert.

[PRESS RELEASE] – STAMFORD, Conn., Sept. 15, 2025 – Curaleaf Holdings Inc., a leading international provider of consumer cannabis products, announced the opening of two new dispensaries: Curaleaf Apopka, located at 1809 E. Semoran Blvd., Apopka, Fla., 32703, and Curaleaf Girard, located at 801 N State St., Girard, Ohio, 44420. With these dual openings, Curaleaf expands to 69 retail locations in Florida, five in Ohio and 157 nationwide.

Curaleaf Apopka strengthens the company’s presence in Central Florida, providing convenient access for registered medical cannabis patients across the Greater Orlando region. Curaleaf Apopka offers a wide portfolio of medical cannabis products, including Curaleaf’s Select brand vapes and edibles, Florida-exclusive Reef flower, Grassroots Dark Heart Collection flower, Anthem pre-rolls, Miss Grass pre-rolls and more. To ensure patient satisfaction, Curaleaf Florida is offering a 72-hour Flower Satisfaction Guarantee on select premium eighths from Grassroots and Reef. The store will operate from 9:00 a.m. to 8:30 p.m. Monday through Saturday and 10 a.m. to 6 p.m. on Sundays.

Meanwhile, Curaleaf Girard marks the company’s first dispensary within the city of Girard, and enhances access for both medical patients and adult-use consumers across Ohio’s Northeast region. The store features a selection including Select BRIQ all-in-one vapes, Grassroots Dark Heart Collection flower, Grassroots pre-rolls, JAMS and Select XBites edibles and Find flower. Curaleaf will be introducing Grassroots and Find pre-rolls in Singles and 5-pack Shorties, as state regulations now allow for the sale of pre-rolls. Curaleaf Girard will be open 9 a.m. to 8 p.m. Monday through Saturday and 9 a.m. to 7 p.m. on Sundays.

“Each new store opening reflects our mission to expand safe, convenient access to high-quality cannabis across the country,” Curaleaf Chairman and CEO Boris Jordan said. “With Apopka, we are deepening our roots in Florida by serving an important new region for medical patients, and with Girard, we are proudly delivering the first licensed dispensary to the city. Together, these milestones show our commitment to patients and consumers who rely on cannabis for their well-being, while reinforcing Curaleaf’s leadership in both established and emerging markets.”

Local celebrations will mark the openings:

• Curaleaf Apopka will host a grand opening on Sept. 19, 2025, from noon to 5 p.m., featuring special promotions, giveaways and an interactive “Live Lounge” livestream with Curaleaf cultivation leaders.
• Curaleaf Girard will celebrate its opening with a ribbon-cutting ceremony alongside the Girard Chamber of Commerce at a later date, featuring exclusive promotions and complimentary refreshments.

For more information on Curaleaf’s dispensaries, products and patient resources, visit www.curaleaf.com.